BioCentury
ARTICLE | Financial News

Halozyme raises $125 million in follow-on

May 19, 2017 7:50 PM UTC

Cancer and drug delivery company Halozyme Therapeutics Inc. (NASDAQ:HALO) raised $125 million through the sale of 10 million shares at $12.50 in a follow-on underwritten by Wells Fargo, Deutsche Bank, Barclays and JMP Securities. The price is a 12% discount to Halozyme's close of $14.16 on Thursday, when it proposed to raise $100 million after market hours.

Halozyme dipped $1.25 to $12.91 on Friday...

BCIQ Company Profiles

Halozyme Therapeutics Inc.